Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 14/20 | 0.57 |
| ▸ | EPAS1 | Q99814 | 14/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Achyrofuran SCHEMBL505137 | 1.00 | HIF1A (0.57) | HIF1AEPAS1MEN1LMNATP53 | |
| SCHEMBL24075656 | 0.75 | HIF1A (0.56) | HIF1AEPAS1MEN1LMNATP53 | |
| SCHEMBL29517025 | 0.74 | HIF1A (0.70) | HIF1AEPAS1MEN1LMNATP53 | |
| SCHEMBL30377279 | 0.72 | HIF1A (0.78) | HIF1AEPAS1 | |
| SCHEMBL29934508 | 0.71 | HIF1A (1.00) | HIF1AEPAS1 | |
| SCHEMBL31237267 | 0.69 | HIF1A (1.00) | HIF1AEPAS1 | |
| SCHEMBL6907224 | 0.69 | HIF1A (1.00) | HIF1AEPAS1 | |
| SCHEMBL6914633 | 0.68 | HIF1A (1.00) | HIF1AEPAS1 | |
| Rhodomyrtoxin B SCHEMBL12827333 | 0.68 | MAPT (1.00) | HIF1AEPAS1MEN1LMNATP53 | |
| SCHEMBL24074938 | 0.67 | PTGES (0.57) | HIF1AEPAS1PTGESALOX5PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12102653-B2 | Ligand regulated protein-protein interaction system | ST. ANNA KINDERKREBSFORSCHUNG (AT) | 2024-10-01 | — | — | US | disclosed |
| US-20240000841-A1 | LIGAND REGULATED PROTEIN-PROTEIN INTERACTION SYSTEM | ST ANNA KINDERKREBSFORSCHUNG (AT) | 2024-01-04 | — | — | US | disclosed |
| US-11844813-B2 | Ligand regulated protein-protein interaction system | ST. ANNA KINDERKREBSFORSCHUNG (AT) | 2023-12-19 | — | — | US | disclosed |
| US-20220041687-A1 | A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS) | ST. ANNA KINDERKREBSFORSCHUNG (AT) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041687-A1 | A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS) | CARS1, CD74, HAVCR2 | HIF1A 2805/4885EPAS1 319/4885MEN1 4288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.